A reassuring presence: An evaluation of Bradford District Hospice at Home service

por Lucas, Beverley, Small, Neil, Greasley, Peter, Daley, Andrew
Publicado 2008

Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation

por Bjursell, Mikael, Ryberg, Erik, Wu, Tingting, Greasley, Peter J., Bohlooly-Y, Mohammad, Hjorth, Stephan
Publicado 2016

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia

por Block, Geoffrey A, Rosenbaum, David P, Yan, Andrew, Greasley, Peter J, Chertow, Glenn M, Wolf, Myles
Publicado 2019

Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With Diabetes

por Cabrera, Claudia S., Lee, Alison S., Olsson, Marita, Schnecke, Volker, Westman, Klara, Lind, Marcus, Greasley, Peter J., Skrtic, Stanko
Publicado 2020

Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus

por Go, Alan S., Yang, Jingrong, Tan, Thida C., Cabrera, Claudia S., Stefansson, Bergur V., Greasley, Peter J., Ordonez, Juan D.
Publicado 2018

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

por Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L.
Publicado 2019

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure

por BJORNSTAD, PETTER, GREASLEY, PETER J., WHEELER, DAVID C., CHERTOW, GLENN M., LANGKILDE, ANNA MARIA, HEERSPINK, HIDDO J.L., VAN RAALTE, DANIËL H.
Publicado 2021

Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data

por Aoki, Yasunori, Cabrera, Claudia S., Ouwens, Mario, Bamberg, Krister, Nyström, Jenny, Raz, Itamar, Scirica, Benjamin M., Hamrén, Bengt, Greasley, Peter J., Rekić, Dinko
Publicado 2022

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

por Sokolov, Victor, Yakovleva, Tatiana, Chu, Lulu, Tang, Weifeng, Greasley, Peter J., Johansson, Susanne, Peskov, Kirill, Helmlinger, Gabriel, Boulton, David W., Penland, Robert C.
Publicado 2020

Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic Diversion

por Karlsson, Cecilia, Wallenius, Kristina, Walentinsson, Anna, Greasley, Peter J, Miliotis, Tasso, Hammar, Mårten, Iaconelli, Amerigo, Tapani, Sofia, Raffaelli, Marco, Mingrone, Geltrude, Carlsson, Björn
Publicado 2020

Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline

por Stefánsson, Bergur V., Heerspink, Hiddo J.L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, Correa-Rotter, Ricardo
Publicado 2021

Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study

por Fitzpatrick, Jesse K, Yang, Jingrong, Ambrosy, Andrew P, Cabrera, Claudia, Stefansson, Bergur V, Greasley, Peter J, Patel, Jignesh, Tan, Thida C, Go, Alan S
Publicado 2022

Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach

por Walsh, Sarah K, Hepburn, Claire Y, Keown, Oliver, Åstrand, Annika, Lindblom, Anna, Ryberg, Erik, Hjorth, Stephan, Leslie, Stephan J, Greasley, Peter J, Wainwright, Cherry L
Publicado 2015

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes...

por Mulder, Skander, Hammarstedt, Ann, Nagaraj, Sunil B., Nair, Viji, Ju, Wenjun, Hedberg, Jonatan, Greasley, Peter J., Eriksson, Jan W., Oscarsson, Jan, Heerspink, Hiddo J. L.
Publicado 2020

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan

por Veenit, Vandana, Heerspink, Hiddo J L, Ahlström, Christine, Greasley, Peter J, Skritic, Stanko, van Zuydam, Natalie, Kohan, Donald E, Hansen, Pernille B L, Menzies, Robert I
Publicado 2023

Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study

por Lee, Nerissa Hoi Ching, Kiddle, Steven J, Chandankhede, Shardul, Agrawal, Shubh, Bean, Daniel M, Hunt, Phillip R, Parker, Victoria E R, Greasley, Peter J, Ambery, Philip
Publicado 2023

Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects

por Westergren, Helena U., Svedlund, Sara, Momo, Remi A., Blomster, Juuso I., Wåhlander, Karin, Rehnström, Erika, Greasley, Peter J., Fritsche-Danielson, Regina, Oscarsson, Jan, Gan, Li-Ming
Publicado 2016

Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19

por Fisk, Marie, Althage, Magnus, Moosmang, Sven, Greasley, Peter J., Cope, Andrew P., Jayne, David RW., Galloway, James, Hall, Frances, Wilkinson, Ian B., Ambery, Philip, Cheriyan, Joseph
Publicado 2021

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

por Whittaker, Andrew, Kragh, Åsa M., Hartleib‐Geschwindner, Judith, Albayaty, Muna, Backlund, Anna, Greasley, Peter J., Heijer, Maria, Kjaer, Magnus, Forte, Pablo, Unwin, Robert, Wernevik, Linda, Ericsson, Hans
Publicado 2019

Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19

por Abraham, George R., Kuc, Rhoda E., Althage, Magnus, Greasley, Peter J., Ambery, Philip, Maguire, Janet J., Wilkinson, Ian B., Hoole, Stephen P., Cheriyan, Joseph, Davenport, Anthony P.
Publicado 2022